Aurobindo Pharma Limited said in a statement that its wholly-owned arm Eugia Pharma Specialties Ltd has obtained final approval from the US health regulator to manufacture and market its generic version of Bortezomib for injection to be applied to treat certain types of cancer.
Aurobindo Pharma said in a regulatory filing that the US Food and Drug Administration (USFDA) has approved a single-dose vial of Bortezomib for injection with a strength of 3.5 mg/vial. The product is a generic version of Takeda Pharmaceuticals USA Inc.'s reference listed medication Velcade.
It went on to say that the product would be available right away. Bortezomib for Injection is used to treat adult patients with multiple myeloma (plasma cell cancer) as well as adult patients with mantle cell lymphoma (lymph node cancer), according to the business.
According to IQVIA data, the approved product has a market size of USD 1.172 billion for the 12 months ending March 2022.
Zydus LifeSciences receives approval USFDA for a generic product
Corona's terror has increased again in India! More than 2,500 cases reported in 24 hours
Which vaccine will be given in the 'booster dose' to those who were vaccinated against Sputnik-V?